POU3F4 CRISPR Activation Plasmid (h): sc-404989-ACT

POU3F4 encodes a POU-domain transcription factor that regulates cell type–specific gene expression programs during embryonic development, with prominent roles in neuroectodermal patterning and inner ear morphogenesis. By binding octamer motifs and cooperating with co-factors, POU3F4 helps coordinate transcriptional networks that shape neuronal differentiation and sensory epithelial organization. Disruption or dysregulation of POU3F4 is linked to inherited forms of hearing impairment and congenital inner ear malformations, making it a useful node for studying developmental gene regulation. In cell-based models, modulating POU3F4 expression supports investigation of lineage specification, chromatin-dependent transcriptional control, and downstream target circuitry relevant to auditory and neural phenotypes.

POU3F4 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous POU3F4 expression without altering the underlying DNA sequence.

POU3F4 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the POU3F4 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the POU3F4 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous POU3F4 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native POU3F4 locus and enabling the study of POU3F4-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of POU3F4 pathway restoration in tumor cells with silenced or reduced POU3F4 expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.